Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,300 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of Scheimpflug and Anterior Segment Optical Coherence Tomography Imaging Parameters for Japanese Patients With Fuchs Endothelial Corneal Dystrophy With and Without TCF4 Repeat Expansions.
Maeno S, Oie Y, Koto R, Nishida N, Yamashita A, Yoshioka M, Kai C, Soma T, Koh S, Yoshihara M, Kawasaki R, Jhanji V, Nakamori M, Tsujikawa M, Nishida K. Maeno S, et al. Among authors: nishida n, nishida k. Cornea. 2024 Feb 1. doi: 10.1097/ICO.0000000000003488. Online ahead of print. Cornea. 2024. PMID: 38300219
Novel PAX6 mutation reported in an aniridia patient.
Winegarner A, Oie Y, Kawasaki S, Nishida N, Nishida K. Winegarner A, et al. Among authors: nishida n, nishida k. Hum Genome Var. 2017 Dec 7;4:17053. doi: 10.1038/hgv.2017.53. eCollection 2017. Hum Genome Var. 2017. PMID: 29238604 Free PMC article.
Quantitative Analysis of the Association Between Follow-Up Duration and Severity of Limbal Stem Cell Deficiency or Visual Acuity in Aniridia.
Komoto S, Oie Y, Kawasaki S, Kawasaki R, Nishida N, Soma T, Koh S, Maruyama K, Usui S, Matsushita K, Tsujikawa M, Maeda N, Nishida K. Komoto S, et al. Among authors: nishida n, nishida k. Invest Ophthalmol Vis Sci. 2020 Jun 3;61(6):57. doi: 10.1167/iovs.61.6.57. Invest Ophthalmol Vis Sci. 2020. PMID: 32589199 Free PMC article.
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab.
Persano M, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Rossari F, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone MA, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Soldà C, Sho T, Niizeki T, Nishida N, Steup C, Bruccoleri M, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Foti S, Camera S, Piscaglia F, Scartozzi M, Cascinu S, Casadei-Gardini A. Persano M, et al. Among authors: nishida n. Target Oncol. 2024 Apr 30. doi: 10.1007/s11523-024-01061-0. Online ahead of print. Target Oncol. 2024. PMID: 38689194
1,300 results